Icahn says will not push opposing MedImmune slate
NEW YORK, April 16 (Reuters) - Billionaire investor Carl Icahn said on Monday he no longer intends to put forth an opposition slate of directors at MedImmune Inc.'s MEDI.O upcoming annual meeting after the biotechnology company announced last week it is exploring a sale.
Icahn, who in February disclosed that he owns 2.8 million shares of MedImmune, said he reserves the right to launch a proxy contest should MedImmune not complete a sale.
((Reporting by Lewis Krauskopf, editing by Gerald E. McCormick; Reuters Messaging: Lewis.Krauskopf.reuters.com@reuters.net; lewis.krauskopf@reuters.com; 646-223-6082))
((Multimedia versions of Reuters Top News are now available for: * 3000 Xtra: visit topnews.session.rservices.com
* BridgeStation: view story .134 For more information on Top News: topnews.reuters.com)) Keywords: ICAHN MEDIMMUNE/
(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWEN6474










